Clinical Role - Payer

Pharmacy Times® is a leader in providing the latest clinical updates, patient counseling tools and innovative solutions to payers, pharmacy benefit managers, formulary chairs and directors, managed care directors, quality assurance directors, and Medicaid/Medicare directors.

PUTT: Pharmacists United for Truth and Transparency
Community Pharmacy Consultant Bruce Kneeland talks with independent pharmacy owner Teresa Dickinson, RPh, about the work of Pharmacists United for Truth and Transparency.
Top 9 Drugs With the Biggest Price Increases Over 2 Years
Nine widely-used medications have experienced substantial price growth since 2016, adding $5.1 billion to overall drug spending.
 
Specialty Drugs Top List of Costliest Drug Price Hikes in New ICER Report
A report by the Institute for Clinical and Economic Review lists the top drugs with the greatest price increases not supported by new clinical evidence.
 
Report: Prescription Drug Prices Climb Nearly 26% in 3 Years
In the wake of California’s drug transparency law, an analysis by state health officials on pricing trends found that drug companies raised the whole acquisition cost dramatically for many drugs.
Cancer Drug Costs May Not Be Factored Into Reimbursement
Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.
Study: Number of Drug
A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.
More Than Just a Number: Assessing The Value of Innovative Treatments
Value assessment frameworks are expected to play a more pivotal role in decisions that affect future patient choice and access.
Out-of-Pocket Costs Grew 7-Fold for Medicare Beneficiaries with Multiple Sclerosis
Rising drug prices for disease-modifying therapies resulted in substantial increases in spending for Medicare beneficiaries with multiple sclerosis.
Importation Plan Aims to Lower US Prescription Drug Prices Amid Safety Concerns
Announced by the HHS and FDA, the plan seeks to safely import medications that would provide a cost savings to consumers, but some pharmacy and other health care professionals have expressed concerns. 
Specialty Drugs Remain a Costly Concern for Employers With No Easy Answers
Costs remain the top concern of healthcare purchasers of pharmacy benefits, but employers are also concerned with ensuring appropriate use of medication and adherence to medication, according to a new report from the Pharmacy Benefit Management Institute (PBMI).
Is There an Alternative to PBM Rebates? ICER Paper Examines 3 Options
With discussion and debate happening for months in Washington, DC, over drug pricing and the role of pharmacy benefit managers (PBMs), the Institute
for Clinical and Economic Review (ICER) published a white paper this week that analyzes 3 possible alternatives to the pharmaceutical rebate system fostered by PBMs.
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
Several efforts are underway nearly a year after the Trump administration released its blueprint to lower drug prices in May 2018, but tracking their outcomes depends on what metric is used to define drug prices, according to a session at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting, held March 25-28 in San Diego, California.
+ Load More